Database

Startups

Main Industry
Biotechnology
Main Product/Service
Calgent’s drug pipeline includes several novel therapeutic candidates. Their lead asset, CAL056 (Hectinib), is an oral first‑in‑class HECT-domain E3 ubiquitin ligase inhibitor for the treatment of multiple myeloma, which has received Orphan Drug Designati
Founded Year
2019
Unified Business No.
85127916
Status
Active
Number of Employees
0
Total Paid-in Capital
338,333,340 (NT$)
Location of Company
Taiwan , Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you. Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person. Please do not contact this platform for company inquiries.
About the Company
Calgent Biotechnology Co., Ltd. is a Taiwan-based biotech startup headquartered in Taipei. Founded in 2019, the company focuses on developing first-in-class small molecule therapeutics to address unmet medical needs. Calgent brings together expertise in translational medicine, pharmacology validation, formulation development, and clinical trial management.



More ↓

Similar Companies

EVERFRONT BIOTECH INC.

1. EF-001 (Cerebraca® Wafer)
2. EF-009 Wafer
3. HK-001
4. EF-031
5. TSCA-001
6. EF-011

Great Novel Therapeutics Biotech & Medicals Corporation

GNTbm focuses on the R&D of oral new drugs in cancer immunotherapy, including tumor microenvironment regulators (TMRs), epigenetic immunoactivators, and immune-regulating multi-kinase inhibitors.

HuniLife Biotechnology, Inc.

HuniLife is committed to developing first-in-class therapeutics for unmet medical need, indicating the innovation-pursuing nature of HuniLife. The products in development at HuniLife are acquired from renowned research institutes or companies through lice